Form 4: Upstream Bio Director Erez Chimovits Reports Significant Transactions Following IPO

Director Erez Chimovits reports conversion of preferred stock and acquisition of common stock following Upstream Bio's initial public offering.

Summary

• On October 15, 2024, Erez Chimovits, a director of Upstream Bio, Inc., reported transactions involving the company's common stock.
• The transactions include the conversion of Series A and Series B redeemable convertible preferred stock into common stock at a 1-for-1.049 ratio immediately prior to the company's IPO.
• Chimovits also reported the acquisition of 165,000 shares of common stock at $17 per share and another acquisition of 660,000 shares at $17 per share.
• Following these transactions, the total amount of common stock beneficially owned indirectly is 4,554,873 shares.
• The shares are held by OrbiMed Israel Partners II, L.P. and OrbiMed Private Investments VIII, LP, with affiliated entities potentially deemed to have beneficial ownership.
• Chimovits disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of transactions related to the IPO. The director's stock purchases are a mildly positive signal, but the disclaimers of beneficial ownership add complexity.

Positives

• The conversion of preferred stock to common stock simplifies the company's capital structure following the IPO.
• Director's purchase of common stock at $17 per share could be interpreted as a sign of confidence in the company's future prospects.

Risks

• The disclaimers of beneficial ownership by Chimovits and affiliated entities could indicate a complex ownership structure.
• The indirect nature of the ownership may obscure the true control and influence over the shares.

Future Outlook

The document does not contain specific forward-looking statements, but the transactions reflect adjustments related to the company's IPO.

Management Comments

• Erez Chimovits disclaims beneficial ownership of the securities reported, except to the extent of his pecuniary interest.

Industry Context

Form 4 filings are standard practice for company insiders following transactions in their company's stock, particularly after significant events like an IPO. This filing provides transparency to the market regarding insider activity.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency of insider transactions.
• The reported transactions are typical for directors and major shareholders following an IPO, as preferred stock often converts to common stock at this time.
• OrbiMed is a well-known healthcare investment firm, and their involvement is not unusual for a biotech company like Upstream Bio.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive signal.
• The conversion of preferred stock simplifies the capital structure, potentially benefiting all shareholders.

Key Dates